Treatment of Delta Hepatitis: Today and in the Future - A review

References

• European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Shirvani-Dastgerdi E, Tacke F. Molecular interactions between hepatitis B virus and delta virus. World J Virol. 2015;4:36–41.
   PubMedGoogle Scholar
• Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–219.
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Rosina F, Saracco G, et al. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. J Hepatol. 1986;3(Suppl 2):S229–S233.
   PubMed Web of Science ®Google Scholar
• Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14:154–157.
   PubMedGoogle Scholar
• Alvarado-Mora MV, Locarnini S, Rizzetto M, et al. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013;18(3 Pt B):541–548.
   Web of Science ®Google Scholar
• Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014;16:365.
   PubMedGoogle Scholar
• Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity. 2006;25:343–348.
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Antonelli G. Antiviral activity of the interferon alpha family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Expert Opin Biol Ther. 2013;13:693–711.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373–381.
   PubMed Web of Science ®Google Scholar
• Paul F, Pellegrini S, Uze G. IFNA2: the prototypic human alpha interferon. Gene. 2015;567:132–137.
   PubMed Web of Science ®Google Scholar
• El-Baky NA, Redwan EM. Therapeutic alpha-interferons protein: structure, production, and biosimilar. Prep Biochem Biotechnol. 2015;45:109–127.
   PubMed Web of Science ®Google Scholar
• Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol. 2013;5:666–675.
   PubMedGoogle Scholar
• Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94.
   PubMed Web of Science ®Google Scholar
• Madejon A, Cotonat T, Bartolome J, et al. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994;19:1331–1336.
   PubMed Web of Science ®Google Scholar
• Gaudin JL, Faure P, Godinot H, et al. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995;15:45–52.
   PubMedGoogle Scholar
• Yurdaydin C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007;14:812–816.
   PubMed Web of Science ®Google Scholar
• Abbas Z, Khan MA, Salih M, et al. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011;12:CD006002.
   Google Scholar
• Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10:721–726.
   PubMed Web of Science ®Google Scholar
• Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–1749.
   PubMed Web of Science ®Google Scholar
• Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–810.
   PubMed Web of Science ®Google Scholar
• Gheorghe L, Iacob S, Simionov I, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011;20:377–382.
   PubMed Web of Science ®Google Scholar
• Samiullah S, Bikharam D. Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012;18:5793–5798.
   PubMed Web of Science ®Google Scholar
• Bahcecioglu IH, Ispiroglu M, Demirel U, et al. Pegylated interferon alpha therapy in chronic delta hepatitis: a one-center experience. Hepat Mon. 2015;15:e24366.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–331.
   PubMed Web of Science ®Google Scholar
• Kabacam G, Dalekos GN, Cakaloglu Y, et al. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol. 2012;23:560–568.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.
   PubMed Web of Science ®Google Scholar
• Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–720.
   PubMed Web of Science ®Google Scholar
• Ormeci N, Bolukbas F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011;58:1648–1653.
   PubMed Web of Science ®Google Scholar
• Karaca C, Soyer OM, Baran B, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013;18:561–566.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Ernst S, et al. Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNArelapse after treatment: The HIDIT-2 study. EASL 2014. J Hepatol. 2014;60(Suppl):2–3.
   Google Scholar
• Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.
   PubMed Web of Science ®Google Scholar
• Triantos C, Kalafateli M, Nikolopoulou V, et al. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther. 2012;35:663–673.
   PubMed Web of Science ®Google Scholar
• Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434–442.
   PubMed Web of Science ®Google Scholar
• Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53:834–840.
   PubMed Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–1638.
   PubMed Web of Science ®Google Scholar
• Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol. 2014;20:12026–12030.
   PubMed Web of Science ®Google Scholar
• Visco-Comandini U, Lapa D, Taibi C, et al. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Dig Liver Dis. 2014;46:348–352.
   PubMedGoogle Scholar
• Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758.
   PubMed Web of Science ®Google Scholar
• Pollicino T, Raffa G, Santantonio T, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol. 2011;85:432–439.
   PubMed Web of Science ®Google Scholar
• Liu F, Campagna M, Qi Y, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9:e1003613.
   PubMed Web of Science ®Google Scholar
• Guedj J, Rotman Y, Cotler SJ, et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014;60:1902–1910.
   PubMed Web of Science ®Google Scholar
• Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30:430–437.
   PubMed Web of Science ®Google Scholar
• Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis. 2012;32:220–227.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37:266–271.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–321.
   PubMed Web of Science ®Google Scholar
• Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:227–232.
   PubMed Web of Science ®Google Scholar
• Chen GY, Su TH, Kao JH. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. J Formos Med Assoc. 2015;114:1140–1141.
   PubMed Web of Science ®Google Scholar
• Kabacam G, Onder FO, Yakut M, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55:645–650.
   PubMed Web of Science ®Google Scholar
• Borzacov LM, de Figueiredo Nicolete LD, Souza LF, et al. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. Int J Infect Dis. 2016;46:82–88.
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, Sierra-Enguita R, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS 2014;28:2389–2394.
   PubMed Web of Science ®Google Scholar
• Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97–102.
   PubMed Web of Science ®Google Scholar
• Boyd A, Miailhes P, Brichler S, et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses. 2013;29:1535–1540.
   PubMed Web of Science ®Google Scholar
• TrehanPati N, Kotillil S, Hissar SS, et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509–520.
   PubMed Web of Science ®Google Scholar
• Singh AK, Sharma MK, Hissar SS, et al. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. J Viral Hepat. 2014;21:439–446.
   PubMed Web of Science ®Google Scholar
• Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–664.
   PubMed Web of Science ®Google Scholar
• Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother. 2003;52:883–886.
   PubMed Web of Science ®Google Scholar
• Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003;112:407–414.
   PubMed Web of Science ®Google Scholar
• Wong NS, Morse MA. Lonafarnib for cancer and progeria. Expert Opin Investig Drugs. 2012;21:1043–1055.
   PubMed Web of Science ®Google Scholar
• Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167–1174.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Idilman R, Choong I, et al. Optimizing the prelination inhibitor Lonafarnib using Ritonavir boosting in patients with chronic delta hepatitis. J Hepatol. 2015;62(Supplement 2):252.
   Web of Science ®Google Scholar
• Engelke M, Mills K, Seitz S, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 2006;43:750–760.
   PubMed Web of Science ®Google Scholar
• Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005;79:1613–1622.
   PubMed Web of Science ®Google Scholar
• Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861–867.
   PubMed Web of Science ®Google Scholar
• Urban S, Bartenschlager R, Kubitz R, et al. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64.
   PubMed Web of Science ®Google Scholar
• Dong Z, Ekins S, Polli JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013;10:1008–1019.
   PubMed Web of Science ®Google Scholar
• Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60:723–731.
   PubMed Web of Science ®Google Scholar
• Blanchet M, Sureau C, Labonte P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antiviral Res. 2014;106:111–115.
   PubMed Web of Science ®Google Scholar
• Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol. 2014;20:7707–7717.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221–1228.
   PubMed Web of Science ®Google Scholar